{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:24:36Z","timestamp":1791908676851,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Through an analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS), we explored the signal strength of adverse reactions (ADRs) related to myopathy caused by the combination of colchicine and statins and gained insight into the characteristics of these myopathy related ADRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted data from the FAERS database about ADRs in individuals with myopathy resulting from the combination of colchicine and statins. The analysis was conducted for the period spanning from January 2004 to December 2023 using the reported odds ratio (ROR) and information component (IC) methods to assess muscle-related ADR signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 18,386 reports of statin myopathy-associated adverse reactions, 348 colchicine myopathy-associated adverse reactions, and 461 muscle-associated adverse reactions due to the combination of the two were collected; the strongest signals of statin myotoxicity events were for necrotizing myositis (ROR 50.47, 95% CL 41.74\u201361.01; IC 3.70 95% CL 3.25\u20134.08); the strongest signal for colchicine myotoxicity events was toxic myopathy (ROR 32.50, 95% CL 19.74\u201353.51; IC 4.97 95% CL 1.89\u20135.10), and the strongest signal for statins combined with colchicine was toxic myopathy (ROR 159.85, 95% CL 111.60\u2013228.98; IC 7.22 95% CL 3.59\u20135.9); muscle-related adverse reactions signals were meaningful when the two drugs were combined in the order of colchicine combined with fluvastatin (ROR 187.38, 95% CL 96.68\u2013363.17; IC 6.99 95% CL 1.65\u20135.68); colchicine combined with simvastatin in 135 cases (ROR 30.08. 95% CL 25.25\u201335.85; IC 4.80 95% CL 3.96\u20135.12); and colchicine combined with rosuvastatin (ROR 25.73, 95% CL 20.16\u201332.83; IC 4.59 95% CL 3.38\u20134.98) versus colchicine combined with atorvastatin (ROR 25.73, 95% CL 22.33\u201329.66; IC 4.59 95% CL 3.97\u20134.91) with almost identical signal intensity, followed by colchicine combined with pravastatin (ROR 13.67, 95% CL 9.17\u201320.37; IC 3.73 95% CL 1.87\u20134.47), whereas no signals were generated for lovastatin or pitavastatin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Similar ADRs can occur when colchicine and statins are used individually or in combination; however, the strength of these reactions may differ. To minimize the risk of drug interactions, statins with less potential interactions, such as lovastatin, pitavastatin, and pravastatin, should be chosen, and myopathy-related indices and symptoms should be closely monitored during use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1418498","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T08:54:10Z","timestamp":1721984050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004\u20132023"],"prefix":"10.3389","volume":"15","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1345\/aph.1E593","article-title":"Acute myopathy in a patient with concomitant use of pravastatin and colchicine","volume":"39","author":"Alayli","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1345\/aph.1E653","article-title":"Possible colchicine rhabdomyolysis in a.fluvastatin-treated patient","volume":"39","author":"Atasoyu","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/mus.20135","article-title":"Cytoskeletal myotoxicity from. simvastatin and colchicine","volume":"30","author":"Baker","year":"2004","journal-title":"Muscle Nerve"},{"key":"B4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1389200222666210114122729","article-title":"HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview","volume":"22","author":"Balasubramanian","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/bdd.378","article-title":"Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL","volume":"25","author":"Barilla","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"key":"B6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.bjp.0703920","article-title":"HMG-CoA reductase. inhibitors and P-glycoprotein modulation","volume":"132","author":"Bogman","year":"2001","journal-title":"Br. J. Pharmocol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40264-013-0055-5","article-title":"Characterization of statin-associated myopathy case reports in Thailand using the health product vigilance center database","volume":"36","author":"Boonmuang","year":"2013","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/RHU.0b013e3182056042","article-title":"Colchicine-induced rhabdomyolysis in a heart\/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin","volume":"17","author":"Bouqui\u00e9","year":"2011","journal-title":"J. Clin. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","article-title":"Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence","volume":"114","author":"Brunham","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-017-0564-8","article-title":"Muscular adverse drug reactions associated with Proton pump inhibitors: a disproportionality analysis using the Italian national network of pharmacovigilance database","volume":"40","author":"Capogrosso Sansone","year":"2017","journal-title":"Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)613505","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/IPC.0b013e3181d608fa","article-title":"The increasing complexity of elderly prescribing: myotoxicity with the combination of daptomycin, atorvastatin, and colchicine prescribing","volume":"18","author":"Erlandson","year":"2010","journal-title":"Infect. Dis. Clin. Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"105866","DOI":"10.1016\/j.intimp.2019.105866","article-title":"Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data","volume":"76","author":"Fan","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jama.296.9.1086","article-title":"An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial","volume":"296","author":"Figueiras","year":"2006","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10067-007-0696-9","article-title":"Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin","volume":"27","author":"Francis","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13256-016-1169-z","article-title":"Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report","volume":"11","author":"Frydrychowicz","year":"2017","journal-title":"J. Med. Case Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.7326\/0003-4819-137-7-200210010-00015","article-title":"Can statins cause chronic low-grade myopathy?","volume":"137","author":"Grundy","year":"2002","journal-title":"Ann. Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fneur.2019.00553","article-title":"Colchicine myopathy: a case series including muscle MRI and ABCB1Polymorphism data","volume":"10","author":"Gupta","year":"2019","journal-title":"Front. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00002826-200209000-00008","article-title":"Colchicine-induced acute myopathy in. a patient with concomitant use of simvastatin","volume":"25","author":"Hsu","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann. Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/RHU.0b013e318156d977RHU.0b013e318156d977","article-title":"Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine","volume":"13","author":"Justiniano","year":"2007","journal-title":"J. Clin. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician\u2019s guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthc. (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.amjmed.2016.12.006amjmed.2016.12.006","article-title":"Risk of colchicine-associated myopathy in gout: influence of concomi-tant use of statin","volume":"130","author":"Kwon","year":"2017","journal-title":"Am. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"34150","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine--update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5694\/mja12.10333","article-title":"Myopathy and possible intestinal dysfunction in a. patient treated with colchicine and simvastatin","volume":"197","author":"Oh","year":"2012","journal-title":"Med. J. Aust."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3191089","DOI":"10.1155\/2016\/3191089","article-title":"An unexpected interaction between Sofosbuvir\/Ledipasvir and Atorvastatin and Colchicine causing rhabdomyolysis in a patient with impaired renal function","volume":"2016","author":"Patel","year":"2016","journal-title":"Case Rep. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/s0002-9343(02)01426-2s0002-9343(02)01426-2","article-title":"Colchicine-induced. rhabdomyolysis","volume":"114","author":"Phanish","year":"2003","journal-title":"Am. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00296-007-0435-1","article-title":"Which statin should be used to-gether with colchicine? Clinical experience in three patients with nephrotic syndrome due to AA type amyloidosis","volume":"28","author":"Sahin","year":"2008","journal-title":"Rheumatol. Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4081\/monaldi.2010.264","article-title":"Rhabdomyolysis induced by co-administration of fluvastatin and colchicine","volume":"74","author":"Sarullo","year":"2010","journal-title":"Monaldi Arch. Chest Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/phar.2674","article-title":"A systematic review of the drug-drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies","volume":"42","author":"Schwier","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2165\/00003495-198800363-00016","article-title":"Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative","volume":"3","author":"Slater","year":"1988","journal-title":"Drugs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatol. Oxf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.neuro.2006.09.003","article-title":"Colchicine and HMG Co-A reduc-tase inhibitors induced myopathy-a case report","volume":"27","author":"Torgovnick","year":"2006","journal-title":"Neurotoxicology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1345\/aph.1H064aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvas-tatin","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00124743-199606000-00011","article-title":"Colchicine neuromyopathy","volume":"2","author":"Uri","year":"1996","journal-title":"J. Clin. Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","article-title":"Colchicine myotoxicity: case reports and literature review","volume":"24","author":"Wilbur","year":"2004","journal-title":"Pharmacotherapy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"772768","DOI":"10.3389\/fphar.2021.772768","article-title":"Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA adverse event reporting system","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1418498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T08:54:13Z","timestamp":1721984053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1418498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1418498"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1418498","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"article-number":"1418498"}}